Innovation Pharmaceuticals Inc (IPIX)

[rmzport]

To date, six cohorts have completed enrollment, with the sixth cohort receiving infusions at 110 mg/m2. Maximum Tolerated Dose (“MTD”) has still not been reached. To date, one patient has competed 7 dosing cycles; 2 patients have completed 5 dosing cycles; 1 patient has completed 4 dosing cycles; 1 patient has completed 3 dosing cycles; 8 patients have completed 2 dosing cycles; and 7 patients have completed 1 dosing cycle. A dosing cycle is 28 days. - See more at: http://cellceutix.com/cellceutix-provides-updates-on-clinical-trials-and-developments-of-its-anti-cancer-anti-psoriasis-and-antibiotic-compounds/#sthash.4Tzgt22s.dpuf
(Marketwire – Jan 15, 2014)
http://cellceutix.com/cellceutix-provides-updates-on-clinical-trials-and-developments-of-its-anti-cancer-anti-psoriasis-and-antibiotic-compounds/#sthash.4Tzgt22s.dpbs